Best Practice in the Multidisciplinary Care of the Patient with HS
November 18, 2022
November 18, 2023
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by an educational grants from AbbVie Inc and Novartis Pharmaceuticals.
- Physicians — maximum of 0.5 AMA PRA Category 1 Credits™
- Nurses — 0.5 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
This educational activity is directed toward dermatologists, nurse practitioners, physician assistants, nurses, and other health care professionals who are involved in the treatment and management of HS. Primary care providers and women’s health professionals who may be involved in the first-line diagnosis of HS are also invited to participate.
The cutaneous symptoms and pain of hidradenitis suppurativa (HS) place a significant burden on patients. Emerging treatments continue to build the arsenal of therapeutic options. However, comorbidities associated with the disease complicate management and underscore the value of a multidisciplinary care approach, including medical and psychosocial support systems. The establishment of treatment goals through patient-focused, multidisciplinary care will be presented in a multimedia format, including a series of video interviews with expert thought leaders integrated into text-based elements.
- Upon completion of this activity, participants should be better able to:
- Develop multidisciplinary care plans for patients with HS based on shared goals of therapy
Colleen Cotton, MD, FAAD
Division of Dermatology
Children’s National Hospital
Raj Chovatiya, MD, PhD, FAAD
Assistant Professor of Dermatology
Northwestern University Feinberg School of Medicine
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 0.5 Contact Hours.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
- Colleen Cotton, MD, FAAD
- Grant/Research Support: Regeneron, Sanofi, Target RWE, Eli Lilly and Company
- Consultant: Pierre-Fabre
- Other: subinvestigator for investigational research: AbbVie, Arcutis Biotherapeutics.
- Raj Chovatiya, MD, PhD, FAAD
- Grant/Research Support: Castle Biosciences
- Consultant: AbbVie, Arcutis, Arena, argenx, Beiersdorf, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, EPI Health, Incyte, L'Oréal, National Eczema Association
- Speaker’s Bureau: AbbVie, Dermavant, Eli Lilly and Company, Incyte, LEO Pharma, Pfizer, Regeneron, Sanofi, and UCB
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.